Intas Pharmaceuticals Ltd, a Rs.8,300 crore plus pharma major from Ahmedabad, has announced a big step which will bring relief to large number of cancer patients in the country for whom the drug – bevacizumab was out of reach till today. Intas’s bevacizumab therapy is priced at Rs.39,995 for the dose strength of 400 mg variant which makes it 60 per cent less than the currently available options.
Every year over 7 lakh patients die due to various types of cancer in India. At Intas we believe in the philosophy of “Patient First”. Hence, in order to relieve the patients from the financial burden associated with the treatment, this cost effective measure is implemented by the organisation. The step is entirely focussed in making the drug treatment accessible to cancer patients in India thus, providing them with a beacon of hope in their fight against the disease.
Bevacizumab is a drug which works by slowing the growth of new blood vessels and is used in treating multiple-cancers like colorectal cancer, ovarian cancer, cervical cancer, lung cancer and recurrent glioblastoma (a type of brain tumour). The drug has been available in India since 2004 but the cost has been so prohibitive that as per eminent clinicians of the country they have been able to give this drug to very few eligible patients.
Intas is a leading, vertically integrated global pharmaceutical company from India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. Intas’ success and incessant growth focus lies in its clinical execution of successful and strategic moves made in the areas of manufacturing, R&D, biotechnology and global operations over the past three decades.
Intas has been growing at 27 per cent CAGR over the last 5 years with an even stronger profit growth. Ranked 10th in the domestic market, the company is one of the top 5 corporates in the Indian chronic therapy category. Intas is also present in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central and Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries.
Source : www.pharmabiz.com
Published on: October 11, 2017